
ã«ããã®COVID-19ã¯ã¯ãã³ãçŽ1500äžååã®æå¹æéãåãã
å èšäºã¯ãã¡ã/Original article here
ãªã¿ã¯çº-é£éŠæ¿åºã¯ãæšå¹ŽCOVAXã¯ã¯ãã³å ±æã¢ã©ã€ã¢ã³ã¹ã«å¯èŽãããã¢ã¹ãã©ãŒãã«ç€Ÿã®çŽ1400äžæ¬ãå«ããçŽ1500äžæ¬ã®æéåãCOVID-19ã¯ã¯ãã³ã廿£ããªããã°ãªããªãã£ãã
å é±äžé¢ã«æåºãããææžã«ããã°ãæ¿åºã¯ä»å¹Ž3æäžæ¬ã4æäžæ¬ã«æéåããšãªã£ãçŽ120äžååã®ã¢ãã瀟補ã¯ã¯ãã³ã廿£ãããšã®ããšã§ããã
ããããã«ããä¿å¥çããã·ã§ãã«ã»ãã¹ãçŽã«æäŸããæ°ããããŒã¿ã«ããã°ãæ¿åºãæšå¹Žä»åœã«å¯èŽããæéåããŸã§ã¡ãŒã«ãŒã®å庫ã«ç ã£ãŠããã¢ã¹ãã©ãŒãã«ç€Ÿã®ã¯ã¯ãã³çŽ1360äžååã«æ¯ã¹ãã°ããã®ç¡é§ã¯ãã±ãã®äžæ»Žã«éããªãã®ã ã
ãšããã®ãã2021幎7æã«ãã«ããŒæ¿åºãäžé£ã®å¯ä»ãå ã ãšçºè¡šããã«ããããããïŒã¢ã¹ãã©ãŒãã«1770äžååãå«ãïŒãã«ããã®åæ°ãå¯ä»ããæç¹ã§ãã°ããŒãã«ãªã¯ã¯ãã³å ±æã¢ã©ã€ã¢ã³ã¹COVAXã¯ãã§ã«ã¢ã¹ãã©ãŒãã«ã§ããµãããã£ãŠããããšã倿ããã®ã§ãã
COVAXã¯ãCOVID-19 Vaccines Global Accessã®ç¥ã§ãäžçä¿å¥æ©é¢ãGAVIã¯ã¯ãã³åçãCoalition for Epidemic Preparedness Innovationsã®å ±åã€ãã·ã¢ããã§ããããã®ç®çã¯ãååœãCOVID-19ã¯ã¯ãã³ã®è³æºãããŒã«ããäžçãããªãã¡çºå±éäžåœãžã®å ¬å¹³ãªã¯ã¯ãã³é 絊ã確ä¿ããããšã§ããã
ã«ããããå¯ä»ãããçŽ1,400äžäººåã®ã¢ã¹ãã©ãŒãã«ç€Ÿè£œã¯ã¯ãã³ãã¢ã©ã€ã¢ã³ã¹ãé åžããªãã£ãçç±ã«ã€ããŠåãããGAVIã³ãã¥ãã±ãŒã·ã§ã³ãã£ã¬ã¯ã¿ãŒã®ãªãªãŒã»ãã£ã³ã¯ããCOVAXããã§ã«åé åœãšãšãã«å€§éã®ïŒã¢ã¹ãã©ãŒãã«ïŒã¯ã¯ãã³ã®é åžã«åãçµãã§ããæã«å°çãã ããšè¿°ã¹ãŸããã
ã«ããä¿å¥çã®åºå ±æ åœè ã¯ãã¢ã¹ãã©ãŒãã«ã®äºé²æ¥çš®ãé åžãããªãã£ãããšã«ã€ããŠãéèŠãå°ãªãã£ãããšã«å ããåé åœã§ã®ã¯ã¯ãã³ã®ãããããšé åžã®ã課é¡ããåå ã§ãããšãç°ãªã説æãè¡ããŸããã
ãã¯ã¯ãã³ã®éèŠãéãããŠããããšãšãåé åœãæµéãåžåã«èª²é¡ãæ±ããŠããããšãããåãå ¥ããããŸããã§ãããã«ããã¯ãã¯ã¯ãã³æ¥çš®ã®éå£ã«å¯ŸåŠããããã«COVAXãšååãç¶ãã, ãä¿å¥ã«ããã®åºå ±æ åœè Charlaine Sleimanã¯ãé»åã¡ãŒã«ã§æžãã.
ä¿å®å ã®ã±ãªãŒã»ãã³ãŒãªãŒè°å¡ã¯ãç¡é§ã«å¯ä»ãããæ³šå°ã¯ãèªç±å ã®äžå§æ«ã®èšŒæ ã§ãããšè¿°ã¹ãã
ãCOVAXãããã䜿çšã§ããªãã£ãã®ã¯æ®å¿µã ããŸããçŽçšè ã®ãã«ã广çã«ç¡é§ã«ãããããšããããªã«AZãè²·ã£ãããšãæ®å¿µã ,ã McCauleyã¯èšã£ã.
ãèªæ°å
ã¯äœã§ãããã ãAã¯çºè¡šãDã¯çŽåããšä»ãå ãããããã®ãããªéèŠãªåé¡ããã«ããã®ããã«å€§éã«è³Œå
¥ããªãã£ãè²§ããåœã
ãå©ããããã®çæ¯ãªåªåã§ã¯ãªããPRã®ããã®ã¹ã¿ã³ãã«ããã®ã¯æ®å¿µãªããšã§ãã
ã¯ã¯ãã³éçºã®åæïŒãããŠã©ã®æ³šå°ã䜿çšèš±å¯ããããã倿ããåïŒã«ãã«ããã¯7ã€ã®ã¡ãŒã«ãŒãš90åãã«ä»¥äžã®äºåè³Œå ¥å¥çŽïŒAPAïŒãçµã³ãŸããããããã®APAã«ãã£ãŠãã«ããã¯ã¯ã¯ãã³ãååšããåã«ãã®éã確ä¿ããããšãã§ããã
ãã®å¥çŽã«ãã£ãŠãã«ããã¯5忬以äžã®ã¯ã¯ãã³ãåãåãããšãä¿èšŒãããããã¯ã«ããäººå šå¡ã«10å以äžã¯ã¯ãã³ãæ¥çš®ããã®ã«ååãªéã§ãããå é±è°äŒã«æåºãããè³æã«ãããšãã«ããã¯4æ21æ¥ã®æç¹ã§1å5340äžæ¬ã®COVID-19ã調éããå©çšã§ããããã«ãããåæã«ãåå匷ã®8300äžååãæäžãããããšã«ãªãã
ãç§ãã¡ã®æŠç¥ã¯æåããã«ããã®äººã ã¯å®å šã§å¹æçãªã¯ã¯ãã³ã«æ©æã«ã¢ã¯ã»ã¹ã§ããããã«ãªããŸãããç§ãã¡ã¯ãã¡æ©ãã¯ã¯ãã³æ¥çš®ãéå§ããçŸåšã§ã¯äžçã§æãé«ãæ¥çš®çãèªã£ãŠããŸãããšã¹ã¬ã€ãã³æ°ã¯è¿°ã¹ãã
ããããã³ãŒãªãŒæ°ã¯ãèªç±å ã® ãäœã§ãããã§ãããããè²·ã ãæŠç¥ã¯ããçŽçšè ã®æåŸ ãè£åãæå€± ãã ãšæ¹å€ããŠããã
ã«ããã¯äžçã§æãã¯ã¯ãã³ã®æåéãå€ãåœã®äžã€ã§ãæäººã®80ïŒ ä»¥äžãå°ãªããšã2åã®äºé²æ¥çš®ãåããŠããã
ãããããããã®æ³šå°ã®å€§éšåã¯ãã¡ã€ã¶ãŒç€Ÿãã¢ãã«ã瀟ã®ãã®ã§ãããä»ã®æ³šå°ã¯ä»æã«è²æž¡ãããªãéããåœåã®éå·å庫ã«çœ®ãããå¯èœæ§ãé«ãããšãæå³ããã
CannãšSleimanã®äž¡æ°ã¯ãäžççã«ã¯ã¯ãã³ã®å ¥æå¯èœæ§ãé«ãŸãã«ã€ããäžå®éã®ã¯ã¯ãã³ã䜿çšãããåã«ç¡é§ã«ãªã£ãŠããŸããšå£°æã®äžã§è¿°ã¹ãŠããŸãã
ãCOVID-19ãšã®éãã«ãããŠåããŠãäžçã®äŸçµŠéããäœæåŸåœã髿åŸåœãåãããååœã®åžååãäžåããŸããããGAVIã®åºå ±æ åœè ã¯ããæäžéãç¡é§ã«ãªããªãããããããææ®µãè¬ããããšã¯éèŠã§ããããã³ãããã¯ãšæŠãéã«ã¯ãç¹ã«ååœãããããã®ç¶æ³ã«å¿ããæé©ãªã¯ã¯ãã³ãéžæã§ããããåªããäžã§ãè©äŸ¡æã«å¯Ÿãããªã¹ã¯èš±å®¹åºŠãé«ããããšãéèŠã§ãããšè¿°ã¹ãŠããŸãã
2021幎æ«ãã2022幎ã«ãããŠãäžçã®ã¯ã¯ãã³äŸçµŠéã¯æ¥éã«å¢å ããŸããããã®çµæãå€ãã®äœæåŸåœãäœæåŸåœããæäžæéãåããåã«æäžã§ããéãããå€ãã®éãä¿æããããã«ãªããŸããããã®çŸåšã®äžççãªäžåè¡¡ãèãããšãå€å°ã®æµªè²»ãé¿ããããŸããããšãã«ããä¿å¥çã¯å¥ã®å£°æã§ææããŠããŸãã
ã€ãŸããæ¿åºãæäžããã¯ã¯ãã³ã®æ°ãæ¯é±æžã£ãŠãããããæ°ãåããªãã»ã©å€ãã®ç¡é§ãªå»æ£ãããå¯èœæ§ããããšããããšã§ãã